Jocelyn Aspa

Jocelyn obtained her diploma in journalism from Langara College in April 2016, just prior to joining INN as a staff writer for the resource sector. Since then, Jocelyn has shifted to covering the life science space and has become managing editor for INN's technology, cannabis and life science divisions. Jocelyn is passionate about niche topics within the life science sector and enjoys shedding light on companies focused on unmet clinical needs.

Prior to joining INN, Jocelyn interned at the Georgia Straight and blogged about the Vancouver Canucks. Before following her career in journalism, Jocelyn spent several years working in law firms. She thrives off the knowledge her background brings to her reporting.

jaspa@investingnews.com

Articles

Tonix Pharmaceuticals Expands Preclinical Pipeline

Tonix Pharmaceuticals Holding (NASDAQ:TNXP) has announced an exclusive agreement to in-license a triple reuptake inhibitor, TNX-1600, to treat post-traumatic stress...

August 20th, 2019

Mersana Therapeutics Expands Study of XMT-1536

Mersana Therapeutics (NASDAQ:MRSN) has announced it has dosed the first patient in its Phase 1 study of XMT-1536 in patients...

August 20th, 2019

Outlook Therapeutics Finishes Patient Enrollment for NOrse 1 Phase 3 Clinical Trial

Outlook Therapeutics (NASDAQ:OTLK) has announced it has finished enrolling patients in its NORSE i Phase 3 clinical trial evaluating ONS-5010...

August 20th, 2019

Cancer Genetics Reports Q2 Financial Results

Cancer Genetics (NASDAQ:CGIX) has released its second quarter results for the quarter ended June 30, 2019. As quoted in the...

August 20th, 2019

Myovant Sciences Finishes Patient Recruitment for Phase 3 Trial

Myovant Sciences (NYSE:MYOV) has announced it has finished enrolling patients in its SPIRIT 2 study, which is the first of...

August 20th, 2019

Nabriva Notches First FDA Nod for Pneumonia Treatment

The FDA's approval of Xenleta is the first of its kind in almost two decades and will treat community-acquired bacterial...

August 19th, 2019

Enlivex Reports Outcome from Sepsis Study

Enlivex Therapeutics (NASDAQ:ENLV) has announced data from its ongoing Phase 1b clinical trial in patients with severe sepsis in addition...

August 19th, 2019